Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage

Summary

This study is a multicenter, prospective, open-label, endpoint-blind, randomized controlled study.Patients receiving surgical treatment for SICH were divided into groups using the random machine method. In addition to conventional treatment for spontaneous intracerebral hemorrhage, patients in the group of early initiation of antiplatelet therapy were given conventional dose of aspirin (100mg, qd) antiplatelet therapy starting from the 3rd day after surgery.An independent group of investigators evaluated cardiac, cerebral and peripheral vascular events and bleeding events at four different time points.To evaluate the benefits and safety of early postoperative initiation of antiplatelet therapy in patients with spontaneous intracerebral hemorrhage.

Conditions

• Spontaneous Intracerebral Hemorrhage

Interventions

DRUG

Antiplatelet Agents

using antiplatelet agents in 3 days after surgery

Sponsors & Collaborators

• The Second Affiliated Hospital of Kunming Medical University

  collaborator OTHER

• First Affiliated Hospital of Fujian Medical University

  collaborator OTHER

• Second Xiangya Hospital of Central South University

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Gangzhou Red Cross Hospital ，Jinan University

  collaborator UNKNOWN

• Beijing Chao Yang Hospital

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Sichuan Academy of Medical Sciences

  collaborator OTHER

• Chongqing General Hospital

  collaborator OTHER

• Binzhou Medical University

  collaborator OTHER

• Fujian Medical University Union Hospital

  collaborator OTHER

• Shanxi Provincial People Hospital

  collaborator UNKNOWN

• Beijing Friendship Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  collaborator OTHER

• Beijing Tiantan Hospital

  lead OTHER

Principal Investigators

• Shuo Wang, MD · Beijing Tiantan Hospital

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-05-01

Primary Completion

2023-02-01

Completion

2023-05-01

Countries

• China

Study Locations